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EFFECT OF 5-AZACYTIDINE ON miRNA EXPRESSION IN HUMAN 
BREAST CANCER CELLS WITH DIFFERENT SENSITIVITY 
TO CYTOSTATICS
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R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, 
NAS of Ukraine, Kyiv 03022, Ukraine
Aim: To analyze expression of miRNA in human breast cancer cells, sensitive and resistant to cisplatin and doxorubicin, and to explore 
possible modification of drug sensitivity via treatment of cells with 5-azacytidine (5-aza), a demethylating agent. Materials and Me­
thods: The study was performed on wild-type MCF-7 cell line (MCF-7/S) and its two sublines MCF-7/Dox and MCF-7/DDP re-
sistant to doxorubicin and cisplatin, respectively. Cells were treated with 5-aza, cisplatin, doxorubicin and their combinations. Relative 
expression levels of miRNA-221, -200b, -320a, -10b, -34a, -122 and -29b were examined, using qRT-PCR. The MTT assay was 
used to monitor cell viability. Results: We compared miRNA expression profiles in MCF-7/S and drug resistant MCF-7/Dox and 
MCF-7/DDP cells. Changes of miRNA-221, -200b, -320a, -10b, -34a, -122 and -29b were observed in both resistant cell lines. The 
most significant differences were found for miRNA-200b (decreased in 50.0 ± 2.6 and 63.0 ± 3.1 times for MCF-7/Dox and MCF-
7/DDP cells, respectively) and for oncogenic miRNA-221 levels (increase in 62.0 ± 5.7 times for MCF-7/Dox and 83.8 ± 7.2 times 
for MCF-7/DDP cells). 5-aza treatment caused an increase of miRNA-10b, -122, -200b levels in MCF-7/S cells, miRNA-34a, 
-10b, -122, -200b and -320a levels in MCF-7/Dox cells and miRNA-34a, -10b, -200b and -320a levels in MCF-7/DDP cells. 
Pretreatment of all studied lines with 5-aza resulted in the increase of their sensitivity to studied cytostatics. In particular, the 
IC50 of doxorubicin decreased by 2-, 4- and 3-fold for cell lines MCF-7/S, MCF-7/Dox and MCF-7/DDP cells, respectively, and 
IC50 of cisplatin in studied cultures decreased by 3-, 2- and 1.5-fold, respectively. Conclusions: It was shown that use of 5-aza can 
modify sensitivity of breast cancer cells to cytotoxic drugs not only by it’s demetylation effect, but also by changes in expression 
of miRNAs, involved in cell proliferation, migration and drug resistance development.
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Oncological diseases remain one of the most com-
mon causes of death. Genetics studies accelerated 
cancer research significantly. Moreover, identifica-
tion of oncogenes and tumor suppressor genes was 
a breakthrough for the development of specific drugs 
to treat cancer, but has not lead to creation of a pana-
cea. Recent studies showed that in addition to ge-
netic disorders, the development of cancer is triggered 
by epigenetic changes. Changes in DNA methylation 
and miRNA expression are important factors, controlling 
oncogenesis and drug resistance development [1, 2].
DNA methylation in oncogenesis. DNA methyla-
tion is a key epigenetic modification that often leads 
to silencing on the gene transcription. Cancer cells are 
characterized by abnormal DNA methylation patterns, 
accompanied by global hypomethylation and gene-
specific hypermethylation, as a rule [2].
DNA methylation occurs when DNA methyltransfe-
rases (DNMT1, DNMT3a and DNMT3b) add the 
methyl group to the cytosine residue of DNA, leading 
to the 5-methylcytosine synthesis. DNA methylation 
occurs mainly in areas rich of so called CpG-islands. 
CpG-islands are found in promoter regions of majority 
of genes, and negative correlation between promoter 
methylation and gene expression is already well known. 
Hypermethy lation of CpG-islands in promoter region 
almost always causes the gene silencing, regardless 
on gene mutations. During breast cancer (BC) develop-
ment, changes of DNA methylation are responsible for 
inactivation of large number of genes, including genes 
that control the cell cycle, steroid receptor genes, genes 
associated with metastasis, resistance to drugs, etc [3].
Changes in DNA methylation lead to genetic instabi-
lity: 5-methylcytosine serve as a transition mutations 
site — through hydrolytic deamination of 5-methylcy-
tosine becomes thymine. This mutation is frequently 
observed in such genes as TP53, RB1 and HRAS. Also, 
epigenetic inactivation of critical genes through pro-
moter hypermethylation is a prerequisite for genetic 
instability — for example, methylation of MLH1, which 
participates in mismatch reparation.
Furthermore, methylation of promoter CpG-islands 
and inactivation of glutathione-S-transferase leads 
to the accumulation of free radicals and further DNA 
damage. Besides some regional gene hypermethy-
lation, genome hypomethylation is one of the important 
characteristics of the tumor, which also contributes 
to genetic instability [4].
It has been suggested that aberrant DNA methyla-
tion can affect the sensitivity of tumor cells to anticancer 
agents altering the expression of genes that are involved 
in the response to the impact of xenobiotics. DNA hyper-
methylation may play an important role in development 
of drug resistance phenotype by inactivation of genes 
that are involved in the cytotoxicity reactions [5].
Significant reduction in the accumulation of metho-
trexate and other drugs in human hepatoma and 
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epidermal carcinoma cells resistant to cisplatin (DDP) 
was demonstrated as the result of silencing of folate-
binding gene FBP. Restoration of this gene expression 
after treatment with a demethylating agent 2-deoxy-
5-azacytidine (5-aza) proved the hypermethylation 
of the FBP promoter in drug resistant cells.
Similar processes occur in testicular tumors; in vivo 
DDP induces promoter hypermethylation de novo. 
In vitro acquired resistance to DDP causes changes 
in the expression of a number of genes, but even in high-
resistant cells the expression of tumor suppressor 
genes is restored after treatment with demethylating 
agents [6].
It was found that expression of several hundred 
genes decreased in DDP resistant cell lines and it can 
be restored by DNMT inhibitors [6–8].
Concluding, the aberrant DNA methylation is a com-
mon event in development of drug resistance in cancer 
cells. Moreover, CpG-methylation leading to gene 
silencing may play an important role in resistance to cy-
tostatic chemotherapy.
miRNAs in cancer development. miRNAs are 
small (18–25 nucleotides) noncoding RNAs, negatively 
regulating expression of target genes through initiation 
of cleavage of their mRNA. miRNA binds to the target 
complementary mRNA, resulting in cleavage and/
or de-adenylation of the latter, or obstructs ribosome 
movement [2].
Usually miRNA genes are transcribed by RNA poly-
merase II. Formed large transcript consists of seve ral 
hundred base pairs, named pri-miRNA, containing 
5՛Cap and poly-A-tail [9].
Then double stranded structures in pri-miRNA are 
recognized by protein DGCR8 (also called “Pasha”), 
which forms microprocessor protein complex with 
an enzyme Drosha that possesses RNAse III domain. 
In the result, approximately 70 bp-length pre-miRNA 
is formed with the shape of a stem-loop-structure (hair-
pin). This pre-miRNA is recognized by Exportin-5 and 
with the participation of Ran-GTPase is transported 
to the cytoplasm [10, 11].
In the cytoplasm, pre-miRNA is digested by enzyme 
Dicer (RNAse III) into a duplex of 22 nucleotides length. 
Dicer initiates the formation of RNA-induced silencing 
complex (RISC). RISC protein family consists of the 
Argonautes (Ago), with endonuclease activity towards 
mRNA that is complementary to microRNA, incorpo-
rated in RISC [12].
RISC is responsible for gene silencing, due to binding 
to 3՛-UTR of the mRNA and repressing its translation [13].
Thus, miRNAs can inhibit the expression of target 
genes through a variety of mechanisms by preven-
ting protein translation without changing of the mRNA 
level or by mRNA degradation. miRNA genes are often 
located in so-called “fragile sites” of chromosomes, 
where often occur deletions, insertions, DNA strand 
breaks (single and double), translocations, transitions, 
amplification etc., making them weak link in the forma-
tion of mutated phenotype [2, 15].
Epigenetic mechanisms in development of drug 
resistance. As was mentioned above, altered expres-
sion of genes, leading to drug resistance development 
can be regulated not only by genetic alterations, but also 
by epigenetic mechanisms. Thus, correction of methy-
lation disturbances and microRNAs expression can 
be used for correction of cancer cells sensitivity [1, 15].
While miRNAs are involved in regulation of many cel-
lular processes, from zygote polarization to cell death, 
upon development of drug resistance only miRNAs, 
responsible for cell proliferation, migration, etc. showed 
altered expression.
Many miRNAs are described as oncogenic — they 
negatively regulate expression of tumor suppressor 
genes, for example, RB1, a cell cycle regulator and 
PTEN (phosphatase and tensin homolog) an inhibitor 
of cell survival/growth. PTEN is the target of several dif-
ferent miRNA — miRNA-21, -216, -221, and -144. Such 
variety of regulatory pathways can be used to overcome 
the drug resistance by maintenance of expression 
of tumor suppressor [1, 16].
Also, there are tumor suppressor miRNAs. Mutations 
in their genes and/or epigenetic silencing of expression 
can cause cancer progression, and also incre asing 
in invasive and migration properties. For example, 
miRNA-200b negatively regulates family of ZEB pro-
teins, responsible for epithelial-mesenchymal transition 
(EMT). Decrease in miRNA-200b expression is one 
of EMT triggers in BC cells [1].
It is well documented that resistance of MCF-7 cells 
to doxorubicin (Dox) is mediated by increase of MDR1 (mul-
tidrug resistance) gene copy numbers. Transfection 
of miRNA-451 causes increase in sensitivity to this cyto-
static, as result of inhibition of MDR1 protein translation 
by degradation of mRNA [17].
As was mentioned already, development of drug 
resistance is often accompanied by disturbances 
in DNA methylation. For example, total DNA methy-
lation is lower in MCF-7 cells, compared with normal 
breast cells. It was proposed that resistance of cancer 
cells to Dox and DDP was developed due to alterations 
in methylation pattern of DNA in the specific regions, 
leading to differentially methylated genes. Such chan-
ges in methylation of promoter CpG-islands, respon-
sible for the specificity of transcription factors are 
essential not only for expression of genes, but also for 
genome stability [18].
Therefore, the aim of the present work was to ana-
lyze expression of miRNA in human BC cells sensitive 
and resistant to DDP and Dox, and explore possible 
modification of drug sensitivity via treatment of the cells 
with 5-aza, a demethylating agent.
MATERIALS AND METHODS
Three sub-lines of breast carcinoma MCF-7 cells 
(obtained from invasive breast ductal carcinoma), 
namely MCF-7/S, sensitive to cytostatics; MCF-7/
Dox — resistant to Dox; and MCF-7/DDP — resis-
tant to DDP were used in our study. Cells were pro-
vided by the Bank of human and animal tissues lines 
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at R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology of NAS of Ukraine and 
described earlier in [19].
All cells were grown in Dulbecco Modified Eagles 
Medium (DMEM, Sigma), supplemented with re-
combinant human insulin (0.01 mg/ml) and 10% fetal 
bovine serum. All cultures were grown in humidified 
atmosphere with 5% CO2 at 37 °C.
Measurement of cell viability, using the MTT as-
say. Ability of living cells to reduce tetrazole (MTT, solu-
tion of the yellow color) into purple crystalline formazan 
by the mitochondrial enzymes allow us to estimate cell 
viability. The resulting intracellular formazan can be so-
lubilized and quantified, using spectrophotometry [20].
For this purpose, cells were cultivated in 96-well 
plates in DMEM, supplemented with insulin (see above) 
for 24 h. The 5-aza, Dox, and DDP were added to media 
at different concentrations.
After 24 h, 10 µl of the MTT dye solution (Sigma, 
USA) (5 mg/ml in phosphate buffer saline) was added 
to the cells; the cells were incubated at the same condi-
tions for 3 h. After centrifugation (1500 rpm, 5 min) the 
supernatant was removed. 100 µl of dimethyl sulfoxide 
(Serva, Germany) was added to each well, to dis-
solve formazan. The absorption was measured, using 
a multiwell spectrophotometer (STAT FAX 2100, USA) 
at a wavelength of 540 nm.
Cytotoxicity of studied agents was studied using 
IC50 and IC30 values [21].
Total RNA isolation. Total RNA extraction was 
performed, using Ribozol RNA Isolation Kit (Amplisens, 
Russia). Concentration of RNA was measured, using 
NanoDrop 2000c Spectrophotometer (Thermo Scien-
tific, USA). The purity of isolated RNA was controlled, 
analyzing the ratio of OD at 260/280 nm. RNA was 
dissolved in TE buffer and stored at −20 °С.
Single-stranded cDNA was synthesized from 
100 ng of total RNA, using TaqMan® MicroRNA Kit for 
reverse transcription.
Real-time quantitative reverse transcription 
polymerase chain reaction (qRT-PCR). Preparation 
of reverse transcription reaction mix was performed ac-
cording to manufacturer’s protocol. Reverse transcrip-
tion was performed at a “Tertsik” (“DNA Tehnologіya”, 
Russian Federation) thermal cycler. qRT-PCR was 
performed on Applied Biosystems 7900HT Fast Real-
Time PCR System using TaqMan® MicroRNA primers 
and manufacturer’s protocol.
Small nucleolar RNA RNU48 was used as an endo-
genous control for normalization of miRNA expression. 
Relative expression of the studied miRNAs was identi-
fied by comparative Ct method [22]. Experiments were 
performed in triplicates for each line, and PCR was 
performed three times for each sample. Expression 
differences between the studied miRNA levels relative 
to control was calculated by the formula:
Fold change = 2−ΔΔCt [22],
where ΔCt (target — control) is equal to the differ-
ence between threshold cycles for miRNA (target) and 
the threshold cycle for RNU48 (control) (ΔCt (target — 
control) = Ct target − Ct control). ΔΔCt = ΔCt (experi-
ment) − ΔCt (control).
Experimental data were analysed using the Stu-
dent’s t-test. P-values less than 0.05 were considered 
statistically significant. Statistical analysis of the obtained 
data was performed, using the STATISTICA 6.0 software.
RESULTS AND DISCUSSION
The analysis of miRNA expression showed that the 
development of resistance to cytotoxic drugs is ac-
companied by a significant decrease in the expression 
of tumor suppressive miRNA-200b: in cells resistant 
to Dox — 50 fold decrease; in cells resistant to DDP — 
63 fold decrease. For the miRNA-320a downregulation 
was 8.5 fold and 3.9 folds, respectively. In addition, the 
increased expression of oncogenic miRNA-221 was ob-
served — 62 fold and 83.8 folds, respectively. miRNA-
10b and miRNA-34a expression changed differently 
in MCF-7/Dox (reduced) and MCF-7/DDP (increased) 
cell lines (Fig. 1).
-80
-60
-40
-20
0 *
* * *
*
*
* *
*
*
*
*
* *
20
40
60
80
100
m
iR
NA
-3
4a
m
iR
NA
-1
0b
m
iR
NA
-2
9b
m
iR
NA
-1
22
m
iR
NA
-2
00
b
m
iR
NA
-2
21
m
iR
NA
-3
20
а
Fo
ld
 c
ha
ng
e
MCF7/Dox / MCF7/S
MCF7/DDP / MCF7/S
Fig. 1. Fold change of miRNAs expression in resistant to Dox and 
DDP MCF-7 cells comparatively to sensitive cell line; *p < 0.05. 
Average ± SD values are shown
5-aza irreversibly binds to DNMT1 during DNA rep-
lication and prevents methylation, reduces the number 
of active DNMT1 molecules in cell and provides a cyto-
toxic DNA adducts formation [23, 24].
The depletion of DNMT1 causes progressive loss 
of methylation upon DNA replication. 5-aza-induced 
hypomethylation affects the entire DNA, and also CpG-
islands in the gene promoter regions; hypomethylation 
of promoters is often associated with induction of tran-
scription [25, 26]. For example, due to 5-aza treatment, 
loss of promoter methylation and induction of transcrip-
tion was shown for BRCA1, the tumor suppressor gene 
that is critical in the ethiology of hereditary and sporadic 
BC [18, 27].
The web resources (at http://refgene.com and 
https://genome.ucsc.edu) to analyze DNA segments 
at a distance of 1.5 kb in up- and downstream regions 
from the transcription start site was used to find CpG-
islands in promoter regions of miRNA-221, -200b, 
-320a, -34a, -10b, -122 and-29b. Several CpG-islands 
were found in areas, where their methylation can prevent 
binding of transcription factors to the promoter.
Summarizing, the promoters of miRNA-200b, -10b 
and -320a are characterized by a high CpG density, that 
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makes these genes more sensitive to demethylation 
influence by described mechanism.
As shown in Table 1, miRNA-10b, -122, -221, and 
-320a showed increased expression in MCF-7/S cells 
upon 5-aza treatment. The most considerable changes 
were detected in miRNA-200b expression (2.55 fold 
increase), and this might lead to inhibition of EMT, 
metastasizing, proliferation and increase susceptibility 
to xenobiotics due to its annotated targets [1].
Table 1. Fold change of miRNAs expression after treatment of MCF-7 cells 
with 5-aza, sensitive and resistant to cytostatics**
miRNA MCF-7/S + 5-aza MCF-7/Dox
MCF-7/Dox 
+ 5-aza
MCF-7/
DDP
MCF-7/DDP 
+ 5-aza
miRNA-34a 1.2 ± 0.1 −4.0±0.2* 1.3 ± 0.2 4.0 ± 0.1* 9.3 ± 0.7*
miRNA-10b 2.1 ± 0.1* −2.0±0.2* 1.3 ± 0.1 5.0 ± 0.9* 8.3 ± 1.3*
miRNA-29b −1.1 ± 0.2 13.0±0.2* 10.2 ± 0.9* 52.4 ± 5.3* 50.2 ± 7.4*
miRNA-122 2.5 ± 0.1* 6.0 ± 0.4* 7.0 ± 1.0* 1.5 ± 0.3* 1.9 ± 0.4*
miRNA-200b 2.55 ± 0.2* −50.0±2.9* −45.1±5.4* −63.0±3.9* −59.1 ± 5.3*
miRNA-221 1.7 ± 0.1* 62.0±4.1* 63.1 ± 7.1* 83.8±8.9* 70.1 ± 9.6*
miRNA-320а 1.89 ± 0.1* −8.5±1.3* −6.1±0.9* −3.9 ± 1.5* 1.7 ± 0.3*
Note: *p < 0.05 compared with MCF-7/S cell culture; ** normalized to the values 
obtained for the MCF-7/S cells without treatment. Average ± SD values are shown.
In Dox-resistant cells upon 5-aza treatment, in-
crease in expression levels of miRNA-34a, -200b and 
-320a was observed — 2.4, 2.9 and 3.3 folds, respec-
tively, while the expression of miRNA-10b and -122 in-
creased only by half compared with control culture.
The 5-aza treatment caused enhanced expression 
of miRNA-34a and -10b up to levels typical for the 
sensitive line. In addition, there was a tendency of diffe-
rences in reduction fold between sensitive and resistant 
cultures to Dox; miRNA-122 showed diminished expres-
sion, while and miRNA-200b and -320a expression was 
elevated. However, changes showed different levels, 
in comparison with sensitive cells.
In MCF-7/Dox cells upon 5-aza treatment, expres-
sion of miRNAs, responsible for apoptosis, sensitivity 
to cytotoxic drugs, cell proliferation and metastasizing, 
was elevated.
DDP resistant cells were characterized by the follow-
ing changes: the level of miRNA-320a increased 2 fold, 
miRNA-10b — 3.32 fold, miRNA-200b — 4 fold, miRNA-
34a — 5 fold, in comparison with the control cells.
In MCF-7/DDP cells, in comparison with the sensi-
tive culture the increase of miRNA-320a, up to the level 
in MCF-7/S cells, enhanced miRNA-200b expression, 
and reduced oncogenic miRNA-221 level were ob-
served. Noteworthy, miRNA-10b, which is responsible 
for invasion and metastasis, was expressed at the higher 
level (Fig. 2).
Changes in drug sensitivity in MCF-7/S, MCF-
7/Dox, and MCF-7/DDP cells upon the treatment 
with 5-aza. The 5-aza is often used in combination with 
DDP, cyclophosphamide, and other drugs used in the 
anti-cancer treatment, in particular, in case of neuro-
blastoma, rhabdomyosarcoma in children, and also 
certain solid tumors [29]. Chekhun et al. [26] showed 
the crucial role of epigenetic regulation in acquisition 
of drug resistance by MCF-7 cells. DNA-methylation 
disturbances are one of the most frequent causes 
of DDP and Dox resistance in these cells.
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Fig. 2. miRNAs expression patterns after 5-aza treatment in resis-
tant MCF-7 cell sublines compared with the control cell cultures; 
*p < 0.05 compared with the control MCF-7/Dox cell culture; 
**p < 0.05 compared with the control MCF-7/DDP cell culture. 
Average ± SD values are shown
The results of the present work show that preliminary 
cultivation of MCF-7 cells with 5-aza resulted in increase 
of cytotoxic effects of DDP and Dox (Table 2). In par-
ticular, the IC50 of Dox decreased by 2, 4 and 3 fold 
for cell lines MCF-7/S, MCF-7/Dox and MCF-7 /DDP 
cells, respectively.
IC50 of DDP in studied cultures decreased by 3, 2 and 
1.5 fold, respectively.
Such modulating effect of 5-aza on cytotoxic effects 
of Dox can be explained by promoter demethylation 
of MDR1 gene, which is responsible in elimination 
of Dox from cells. There are twelve CpG-islands in the 
MDR1 gene promoter, 5 of which remain methylated 
in transformed cells. Increased expression of this gene 
is usually caused by its amplification. It is proposed 
that demethylation facilitates binding of regulatory 
elements to the promoter, inhibiting the transcription 
of this gene [26].
Also, increased miRNA-320a is involved in MDR1 si-
lencing, as well as miRNA-34a does [1, 17, 30].
It was proposed earlier, that increase of sensitivity 
to DDP could be associated with the following mecha-
nisms — 5-aza causes DNA demethylation, and this 
leads to changes in expression of genes responsible 
for the transport of DDP into the cell. DDP is associated 
with GG, AG and GNG motifs, forming intra-chain DNA 
adducts and extra- and intrastrand G-G DNA crosslinks. 
Demethylation of CpG-rich areas increases their vulner-
ability to DDP and, thereby increases sensitivity [19, 
26, 31].
Table 2. Increased sensitivity of BC cells to anticancer drugs after treatment with 5-aza
IC50, µM
MCF-7/S MCF-7/DOX MCF-7/DDP
Dox DDP Dox DDP Dox DDP
Control 4.1 ± 0.3 15.3 ± 1.3 23.3 ± 2.1 16.0 ± 1.0 12.4 ± 1.2 93.3 ± 7.0
10 days with 5-aza 3.5 ± 0.2* 10.5 ± 1.9* 13.7 ± 1.3* 11.9 ± 0.8* 10.2 ± 1.2* 87.4 ± 3.0*
20 days with 5-aza 2.9 ± 0.7* 7.2 ± 1.4* 6.3 ± 1.1* 9.7 ±1.5* 6.9 ± 0.9* 55.9 ± 2.1*
30 days with 5-aza 2.4 ± 0.3* 5.4 ± 0.3* 5.2 ± 0.2* 4.4 ± 2.4* 4.6 ± 0.2* 45.2 ± 6.3*
Note: *p < 0.05 compared with the control cell culture. Average ± SD values are shown.
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Another mechanism to restore the sensitivity to DDP 
is increased miRNA-200b expression. This miRNA 
modulates iron metabolism, thus, enhancing oxidative 
stress in cancer cells [19, 32].
In conclusion, we have shown that miRNA expression 
was increased in BC cells upon 5-aza treatment, due 
to promoter DNA demethylation. At such conditions res-
toration of expression of miRNA-10b, -34a, -200b, and 
-320a was observed in MCF-7 sublines resistant to Dox 
and DDP. Importantly, this increased sensitivity of prior 
resistant cells to treatment with anti-cancer drugs.
We may speculate that this phenomenon is due 
to the enhanced epigenetic control of miRNA expres-
sion upon treatment with 5-aza. The obtained data 
create the basis for further in vivo investigations.
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